Encephalopathy cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
(Created page with "{{Encephaloapthy}} {{CMG}} ; {{AE}} {{ADI}} ==Overview== ==Financial Costs== ==References== {{reflist|2}} {{WH}} {{WS}} Category:Grammar") |
|||
| Line 5: | Line 5: | ||
==Financial Costs== | ==Financial Costs== | ||
* Cost effectiveness of various therapies depends on the condition. | |||
* Hypothermia - Neonatal Encephalopathy - The incremental cost per disability-free life year gained was US$28,124 (£19,931 ; €26,920) as per the data of 2006 Organisation for Economic Co-operation and Development (OECD). <ref name="pmid20561343">{{cite journal |author=Regier DA, Petrou S, Henderson J, ''et al.'' |title=Cost-effectiveness of therapeutic hypothermia to treat neonatal encephalopathy |journal=Value Health |volume=13 |issue=6 |pages=695–702 |year=2010 |pmid=20561343 |doi=10.1111/j.1524-4733.2010.00731.x |url=}}</ref> | |||
==References== | ==References== | ||
Revision as of 05:17, 23 July 2012
Template:Encephaloapthy Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]
Overview
Financial Costs
- Cost effectiveness of various therapies depends on the condition.
- Hypothermia - Neonatal Encephalopathy - The incremental cost per disability-free life year gained was US$28,124 (£19,931 ; €26,920) as per the data of 2006 Organisation for Economic Co-operation and Development (OECD). [1]
References
- ↑ Regier DA, Petrou S, Henderson J; et al. (2010). "Cost-effectiveness of therapeutic hypothermia to treat neonatal encephalopathy". Value Health. 13 (6): 695–702. doi:10.1111/j.1524-4733.2010.00731.x. PMID 20561343.